Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Panzuto, F; Merola, E; Pavel, ME; Rinke, A; Kump, P; Partelli, S; Rinzivillo, M; Rodriguez-Laval, V; Pape, UF; Lipp, R; Gress, T; Wiedenmann, B; Falconi, M; Delle Fave, G.
Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Oncologist. 2017; 22(4):409-415
Doi: 10.1634/theoncologist.2016-0351
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Kump Patrizia
- Lipp Rainer
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Several risk factors predict clinical outcome in gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs); however, the impact of their combination has not been investigated so far. A retrospective analysis of stage IV GEP-NENs was performed. Multivariate analysis for progression of disease (PD) was performed by Cox proportional hazards method to obtain a risk score. Area under the curve obtained by receiver operating characteristic analysis was used to assess the score performance. Progression-free survival analysis was performed by Kaplan-Meier method. Two hundred eighty-three stage IV GEP-NENs were evaluated, including 93 grade 1 neuroendocrine tumors (32.9%), 153 grade 2 neuroendocrine tumors (54%), and 37 grade 3 neuroendocrine carcinomas (13.1%). Independent risk factors for PD were Ki67, proportion of metastatic liver involvement, and presence of extra-abdominal metastases. The risk score was calculated as follows: (0.025 × Ki67) + [(0 if no liver metastases or liver involvement <25%) OR (0.405 if liver involvement 25%-50%) OR (0.462 if liver involvement >50%)] + [(0 if no extra-abdominal metastases) OR (0.528 if extra-abdominal metastases present)]. The risk score accuracy to predict PD was superior compared with the G grading system (area under the curve: 0.705 and 0.622, respectively). Three subgroups of patients with low, intermediate, and high risk of PD according to risk score were identified, median progression-free survival being 26 months, 19 months, and 12 months, respectively. In stage IV GEP-NENs, a risk score able to predict PD was obtained by combining Ki67, proportion of metastatic liver involvement, and presence of extra-abdominal metastases. The score may help to discriminate patients with different progression risk level to plan tailored therapeutic approaches and follow-up programs. The Oncologist 2017;22:409-415Implications for Practice: Clinical outcome of patients with advanced gastro-entero-pancreatic neuroendocrine neoplasms is affected by several risk factors, including the proliferative index Ki67, extension of liver metastases, and the presence of distant extra-abdominal lesions. A risk score that combines these variables may help physicians dealing with these diseases to plan the optimal therapeutic approach and follow-up program. © AlphaMed Press 2017.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Disease Progression -
- Disease-Free Survival -
- Female -
- Humans -
- Intestinal Neoplasms - diagnosis
- Intestinal Neoplasms - epidemiology
- Intestinal Neoplasms - pathology
- Male -
- Middle Aged -
- Neoplasm Metastasis -
- Neoplasm Staging -
- Neuroendocrine Tumors - diagnosis
- Neuroendocrine Tumors - epidemiology
- Neuroendocrine Tumors - pathology
- Pancreatic Neoplasms - diagnosis
- Pancreatic Neoplasms - epidemiology
- Pancreatic Neoplasms - pathology
- Proportional Hazards Models -
- Risk Factors -
- Stomach Neoplasms - diagnosis
- Stomach Neoplasms - epidemiology
- Stomach Neoplasms - pathology
- Find related publications in this database (Keywords)
- Neuroendocrine tumors
- Prognosis
- Risk score
- Disease progression
- Ki67
- Metastases